SE506024C2 - Melanomassocierat P97 antigen och immunogen komposition - Google Patents

Melanomassocierat P97 antigen och immunogen komposition

Info

Publication number
SE506024C2
SE506024C2 SE8700466A SE8700466A SE506024C2 SE 506024 C2 SE506024 C2 SE 506024C2 SE 8700466 A SE8700466 A SE 8700466A SE 8700466 A SE8700466 A SE 8700466A SE 506024 C2 SE506024 C2 SE 506024C2
Authority
SE
Sweden
Prior art keywords
cells
denatured
protein antigen
substantially pure
protein
Prior art date
Application number
SE8700466A
Other languages
English (en)
Swedish (sv)
Other versions
SE8700466D0 (sv
SE8700466L (sv
Inventor
Joseph P Brown
Charles D Estin
Gregory D Plowman
Timothy M Rose
Karl E Hellstrom
Ingegerd Hellstrom
Anthony F Purchio
Shiu-Lok Hu
Sridhar Pennathur
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26676698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE506024(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/007,230 external-priority patent/US5262177A/en
Application filed by Oncogen filed Critical Oncogen
Publication of SE8700466D0 publication Critical patent/SE8700466D0/xx
Publication of SE8700466L publication Critical patent/SE8700466L/
Publication of SE506024C2 publication Critical patent/SE506024C2/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE8700466A 1986-02-07 1987-02-06 Melanomassocierat P97 antigen och immunogen komposition SE506024C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82731386A 1986-02-07 1986-02-07
US07/007,230 US5262177A (en) 1986-02-07 1987-01-27 Recombinant viruses encoding the human melanoma-associated antigen

Publications (3)

Publication Number Publication Date
SE8700466D0 SE8700466D0 (sv) 1987-02-06
SE8700466L SE8700466L (sv) 1987-08-08
SE506024C2 true SE506024C2 (sv) 1997-11-03

Family

ID=26676698

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8700466A SE506024C2 (sv) 1986-02-07 1987-02-06 Melanomassocierat P97 antigen och immunogen komposition
SE9202934A SE9202934D0 (sv) 1986-02-07 1992-10-07 Vacciner mot melanom

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9202934A SE9202934D0 (sv) 1986-02-07 1992-10-07 Vacciner mot melanom

Country Status (18)

Country Link
JP (3) JP2664673B2 (fr)
BE (1) BE1000175A3 (fr)
CH (1) CH675424A5 (fr)
DE (1) DE3703702C2 (fr)
DK (1) DK63287A (fr)
ES (2) ES2012815A6 (fr)
FI (1) FI94836C (fr)
GR (1) GR870195B (fr)
HU (1) HU209144B (fr)
IE (1) IE59597B1 (fr)
IT (1) IT1222359B (fr)
MX (1) MX9203574A (fr)
NL (1) NL8700285A (fr)
NO (1) NO178931C (fr)
NZ (1) NZ219192A (fr)
OA (1) OA08478A (fr)
PT (1) PT84255B (fr)
SE (2) SE506024C2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821925A1 (de) * 1998-05-15 1999-11-18 Roehnisch Tim Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Also Published As

Publication number Publication date
SE8700466D0 (sv) 1987-02-06
JP2664673B2 (ja) 1997-10-15
DK63287A (da) 1987-08-08
NZ219192A (en) 1991-10-25
JPS62294698A (ja) 1987-12-22
JPH08280390A (ja) 1996-10-29
PT84255A (en) 1987-03-01
NO870475L (no) 1987-08-10
FI870501A0 (fi) 1987-02-06
IE59597B1 (en) 1994-03-09
GR870195B (en) 1987-06-10
IT1222359B (it) 1990-09-05
NL8700285A (nl) 1987-09-01
ES2012815A6 (es) 1990-04-16
FI94836C (fi) 1995-11-10
NO870475D0 (no) 1987-02-06
SE8700466L (sv) 1987-08-08
OA08478A (fr) 1988-07-29
SE9202934D0 (sv) 1992-10-07
ES2017258A6 (es) 1991-01-16
FI94836B (fi) 1995-07-31
MX9203574A (es) 1992-07-01
NO178931B (no) 1996-03-25
PT84255B (pt) 1989-11-30
NO178931C (no) 1996-07-03
IT8719291A0 (it) 1987-02-06
IE870319L (en) 1987-08-07
FI870501L (fi) 1987-08-08
BE1000175A3 (fr) 1988-07-12
JPH09135692A (ja) 1997-05-27
HU209144B (en) 1994-03-28
DE3703702A1 (de) 1988-02-18
HUT43107A (en) 1987-09-28
DE3703702C2 (de) 1997-07-10
DK63287D0 (da) 1987-02-06
CH675424A5 (en) 1990-09-28

Similar Documents

Publication Publication Date Title
US5262177A (en) Recombinant viruses encoding the human melanoma-associated antigen
US5141742A (en) Vaccines against melanoma
Oren et al. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins
KR960013578B1 (ko) 호흡성 신시아 비루스 : 백신 및 진단검사법
JP3869476B2 (ja) 黒色腫関連抗原ポリペプチド、そのエピトープ及び黒色腫のワクチン
CA2206343C (fr) Reactifs et procede de ciblage des recepteurs mutants du facteur de croissance de l'epiderme
AU2021261945B2 (en) Compositions and methods for generating an immune response to a tumor associated antigen
WO1992005248A1 (fr) Expression de proteines virales du papillome humain et utilisation dans des compositions immunogeniques
GB2188637A (en) Vaccines against melanoma
JP3262787B2 (ja) 豚コレラウイルスワクチン
WO2011091716A1 (fr) Variante du récepteur du facteur de croissance épidermique
JPH03164183A (ja) 脳由来の膜蛋白質発現系
JP2006525787A (ja) アカゲザルＨＥＲ２／ｎｅｕ、これをコードするヌクレオチド及びその使用
FI94836B (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
CA2067469C (fr) Vaccin recombinant contre la maladie de marek
US6518045B1 (en) Feline cytokine protein
WO2004052927A1 (fr) Gene associe a la calvitie et polypeptide code par ce gene, et utilisations correspondantes
JP3417950B2 (ja) マイコプラズマ属細菌の新規な抗原タンパク質、その遺伝子、および組み換えベクターとその利用
KR100282284B1 (ko) Mn 유전자 및 단백질
WO2004022589A1 (fr) Marqueur tumoral et ses applications
US20080096833A1 (en) Polytpeptide Specific To Liver Cancer, Polynucleotide Coding For The Polypeptide, And Rna Molecule Inhibiting Expression Of The Polypeptide
EP1386965A1 (fr) Proteine du canal cation dependant du potentiel
WO2000020442A1 (fr) Peptides antigenes specifiques aux tumeurs

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8700466-9

Format of ref document f/p: F